[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"h-pylori-eradication\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:h-pylori-eradication":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,50],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":31,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":5},"100606721","phase-2-efficacy-of-carminal-in-helicobacter-pylori-gastritis-100606721",false,"NCT07179237","Efficacy of Carminal in Helicobacter Pylori Gastritis","Evaluation of the Efficacy of Carminal on the Gastric Mucosa in Patients With Helicobacter Pylori Positive Gastritis","Inclusion Criteria:\n\n* Patients aged 18 years or older\n* Patients with clinical symptoms of dyspepsia\n* Patients diagnosed with Helicobacter pylori positive gastritis, confirmed by upper endoscopy with histology\n* Patients who give written informed consent to participate in the study\n\nExclusion Criteria:\n\n* Patients with peptic ulcer disease\n* Patients with previous gastric surgery\n* Patients with current malignancy or the history of any previous malignancies\n* Patients taking another investigational product, or have taken any investigational product in the last year\n* Patients with known hypersensitivity to any ingredients found in the investigational product.\n* Decompensated intercurrent illnesses, including: active infections, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, liver disease, and psychiatric illnesses that may limit adherence to the requirements of the clinical trial, or any other special condition that, according to the physician's judgement, jeopardises the patient's health or life during participation in the trial.\n* Planned pregnancy for the duration of trial, pregnancy, breast feeding, or postpartum period.\n* Patients with human immunodeficiency virus (HIV).","ALL","18 Years",{"count":19,"type":20},80,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","Eighty patients will be included and randomized in two groups, one group (40 patients) will be administered 30 ml of the supplement Carminal, once a day, plus therapy for HP gastitis and the control group (40 patients) will be given standard therapy for HP gastritis with placebo. Treatment will begin after complection of upper endoscopy with histology results from biopted gastric mucosa. Treatment with Carminal will be continued after successful HP eradication during 12 weeks. The final evaluation will take place 12 weeks after the last Carminal intake, when control endoscopy with histology will be performed. The study will last approximately 24 weeks.",[26,27,28,29,30],"H Pylori Gastritis","H Pylori Infection","H Pylori Eradication","Gastritis Associated With Helicobacter Pylori","Gastric Mucosal Lesion",[32,33,34,35,36,37],"Antioxidant","Aloe vera","Food Supplement","Helicobacter Pylori","Gastritis","Gastric mucosa","RECRUITING","2025-09-16",{"date":41,"type":42},"2025-09-17","ACTUAL",{"date":44,"type":42},"2025-08-04",{"date":46,"type":20},"2026-10-05",{"name":48,"class":49},"Catalysis SL","INDUSTRY",{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":57,"sex":16,"minAge":58,"maxAge":59,"enrollmentInfo":60,"targetDuration":4,"studyType":62,"phases":4,"briefSummary":63,"conditions":64,"keywords":67,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":82},"100537236","h-pylori-screen-and-treat-study-in-a-population-of-young-adults-100537236","NCT06275204","H. Pylori Screen-and-treat Study in a Population of Young Adults","Multicentric Transnational H. Pylori Screen-and-treat Study in a Population of Young Adults","Inclusion Criteria:\n\n* Young adults (generally 30 - 34 years of age)\n\nExclusion Criteria:\n\n* Patients with mental or developmental limitations who cannot provide a fully-informed consent to participate (based on the assessment from research or patient's personal physician team)\n* Previously treated H. pylori infection\n* History of partial or total gastric resection due to benign or malign lesions",true,"30 Years","34 Years",{"count":61,"type":20},6800,"OBSERVATIONAL","Gastric cancer remains a major challenge to public health on a global scale. H. pylori related cancer burden contributes to the largest proportion of cancer cases attributable to infections in Europe. Considering its absolute burden and persisting disparities, in addition to the substantial prevalence of H. pylori infection worldwide that is treatable, gastric cancer is a logical target for urgent action for prevention. Population-based H. pylori test-and-treat has therefore been proposed as a strategy for gastric cancer prevention. To fill the gaps in knowledge about gastric cancer prevention through H. pylori screening and eradication in younger adults, a study of a population-based H. pylori test-and-treat strategy in Ireland, Croatia, Latvia, Poland, Romania and Slovenia.\n\nMain goals of this study are to assess future program processes, feasibility, acceptability and effectiveness. In total of 6,800 adults aged 30-34 will be tested for H. pylori infection. They will be randomly selected to represent the chosen population and invited to participate in the study based on informed consent. Confirmed infections will be treated by available combined therapy in line with treatment guidelines and the success of eradication will be retested during a control check-up.\n\nPatients who will provide their consent to participate will undertake an interview about the risk factors in early childhood and their habits regarding alcohol consumption and use of tobacco. Compliance to testing and treatment, treatment results, adverse effects and reasons for dropping out will be additionally monitored. Gathered data will be analysed in alignment with our research questions. The investigators will disseminate reports and present the results to both the general public and the scientific community in order to foster future developments in gastric cancer prevention.",[65,27,28,66],"Gastric Cancer","H-pylori",[68,69,70,71],"H. pylori","gastric cancer","eradication therapy","screening","2024-03-03",{"date":74,"type":42},"2024-03-05",{"date":76,"type":20},"2024-03-04",{"date":78,"type":20},"2026-12-01",{"name":80,"class":81},"University of Latvia","OTHER",7]